Showing results (161-170 of 537) with videos related to

Sort By:
Pageof 54
Blood|November 20, 2012
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutationsSebastian Schwind, Colin G Edwards, Deedra Nicolet, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2005
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell linesJim J Xiao, Ying Huang, Zunyan Dai, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Blood|February 23, 2008
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphomaLuca Paoluzzi, Mithat Gonen, Jeffrey R Gardner, et al.
International Journal of Molecular Sciences|June 24, 2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 ActivationDinh Hoa Hoang, Ralf Buettner, Melissa Valerio, et al.
Blood|November 19, 2005
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationMario Notari, Paolo Neviani, Ramasamy Santhanam, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamideOwen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
Leukemia & Lymphoma|January 2, 2024
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinibDat Ngo, Jose Tinajero, Shanpeng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2022
MicroRNA networks in FLT3-ITD acute myeloid leukemiaDinh Hoa Hoang, Dandan Zhao, Sergio Branciamore, et al.
Pageof 54